FORBION
FORBION is a Pre-seed, Seed, Series A and Series C+ fund in the US and Europe writing up to $30M checks into Healthcare, food, agriculture, materials, environmental-tech, food-tech and materials-tech.
- Stages
- Pre-seed, Seed, Series A, Series C+
- Sectors
- Healthcare, food, agriculture, materials, environmental-tech, food-tech, materials-tech
- Check size
- up to $30M
- Invests in
- US-wide, Europe
- Actively investing
- Yes
- Founded
- 2006
- Assets under management
- $5.5B
- Website
- forbion.com
Thesis
Forbion is a global venture capital firm specializing in life sciences, with a dual focus on human health and planetary health. They invest across all stages of biopharmaceutical drug development, from pre-clinical to late-stage, targeting innovative biotech companies addressing unmet medical needs. Key human health areas include immunology, oncology, rare diseases, cardiovascular/metabolic diseases, CNS disorders, ophthalmology, respiratory diseases, nephrology, and infectious diseases. For their BioEconomy fund, they target companies developing sustainable solutions in food, agriculture, materials, and environmental technologies. Forbion typically leads or co-leads investment rounds and manages multiple fund strategies: Ventures, Growth Opportunities, and BioEconomy. As of October 2024, they manage over $5.5 billion in AUM. Their growth fund can invest up to €30 million per deal in later-stage biotechnology companies.
Common questions
Does FORBION invest at the Pre-seed stage?
Yes. FORBION lists Pre-seed, Seed, Series A and Series C+ among the stages it invests in.
What check size does FORBION write?
FORBION writes up to $30M checks.
Where does FORBION invest?
FORBION invests in the US and Europe.